Integra LifeSciences Holdings Corporation (IART)
NASDAQ: IART · Real-Time Price · USD
18.45
+1.07 (6.16%)
Aug 13, 2026, 12:24 PM EDT - Market open
IART Financials Overview
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 1,648 | 1,635 | 1,611 | 1,542 | 1,558 | 1,542 |
Revenue Growth | 1.60% | 1.54% | 4.47% | -1.03% | 0.99% | 12.43% |
Gross Profit Gross Profit Growth | 864.58 | 831.62 | 882.06 | 884.74 | 970.31 | 944.64 |
Operating Income Operating Income Growth | 65.56 | -493.37 | 28.41 | 111.53 | 238.92 | 197.23 |
Net Income Net Income Growth | -7.24 | -516.47 | -6.94 | 67.74 | 180.55 | 169.08 |
Earnings Per Share EPS Growth | -0.09 | -6.74 | -0.09 | 0.84 | 2.16 | 1.98 |
EPS Growth | - | - | - | -61.11% | 9.09% | 26.11% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Tissue Reconstruction Tissue Reconstruction Growth | 439.37 | 434.73 | 466.89 | 482.58 | 538.1 | 517.22 |
Specialty Surgery Specialty Surgery Growth | 1,208 | 1,201 | 1,144 | 1,059 | 1,020 | 1,025 |
Total Total Growth | 1,648 | 1,635 | 1,611 | 1,542 | 1,558 | 1,542 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 274.08 | 263.74 | 273.57 | 309.1 | 456.66 | 513.45 |
Total Debt Total Debt Growth | 2,049 | 2,033 | 1,985 | 1,682 | 1,615 | 1,651 |
Net Cash (Debt) Net Cash Growth | -1,775 | -1,769 | -1,711 | -1,373 | -1,159 | -1,138 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | -23.00 | -23.08 | -22.22 | -17.09 | -13.87 | -13.31 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 85.33 | 50.38 | 129.38 | 139.96 | 264.47 | 312.43 |
Capital Expenditures CapEx Growth | -59.53 | -81.44 | -104.42 | -66.87 | -42.34 | -48.02 |
Free Cash Flow Free Cash Flow Growth | 25.8 | -31.05 | 24.96 | 73.09 | 222.13 | 264.41 |
Free Cash Flow Growth | - | - | -65.84% | -67.09% | -15.99% | 60.30% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 52.47% | 50.86% | 54.77% | 57.39% | 62.29% | 61.24% |
Operating Margin | 3.98% | -30.17% | 1.76% | 7.23% | 15.34% | 12.79% |
Pretax Margin | -0.01% | -34.46% | -1.13% | 5.26% | 13.73% | 13.92% |
Profit Margin | -0.44% | -31.58% | -0.43% | 4.39% | 11.59% | 10.96% |
FCF Margin | 1.57% | -1.90% | 1.55% | 4.74% | 14.26% | 17.14% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 13, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | - | - | - | 51.85 | 25.96 | 33.83 |
Forward PE | 7.30 | 5.21 | 8.83 | 12.94 | 16.16 | 20.19 |
P/FCF Ratio | 52.39 | - | 70.11 | 46.58 | 21.12 | 21.48 |
PS Ratio | 0.82 | 0.59 | 1.09 | 2.21 | 3.01 | 3.68 |